Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

Conditions

• Diagnosis of Cancer of Various Organs

Eligibility Criteria

Sex

ALL

Age

21 Years - 80 Years

Healthy Volunteers

Accepted

Interventions

• Blood Draw — OTHER
  Blood Draw

Study Details

ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.

Key Dates

Start date

Apr 5, 2018

Status verified

Apr 2026

Primary completion

Jun 13, 2029

Completion

Sep 13, 2029

Study Design

Enrollment

20,000 participants (estimated)

Arms

• Arm: Non-cancer
  10,000 asymptomatic individuals without prior history of cancer
• Arm: Cancer
  10,000 individuals with confirmed malignancy

Primary Outcome Measure

Detection of cancer signal in the cancer cohort [ Time Frame: Baseline ]

Central Contacts

• Melissa Peters, MA, PMP, CCRC
  619-277-2160
  [email protected]

Locations (1)

Find similar trials in San Diego, CA